Oscar Health Reports Significant Q1 Profitability Turnaround, Reaffirms 2026 Guidance
OSCR sits 86% above its 52-week low of $10.69.
Summary
Oscar Health reported a significant return to profitability in Q1 2026 with $679.0 million in net income and improved operational metrics, reaffirming its full-year guidance despite a revenue miss.
Key Events · Earnings and Guidance · OSCR
-
Significant Profitability Turnaround
The company reported a net income of $679.0 million for Q1 2026, a substantial increase from $275.3 million in Q1 2025 and a major reversal from the $443.15 million net loss in fiscal year 2025. Diluted EPS rose to $2.07 from $0.92 year-over-year.
-
Improved Operational Efficiency
The Medical Loss Ratio (MLR) improved to 70.5% in Q1 2026 from 75.4% in Q1 2025, and the SG&A expense ratio decreased to 15.2% from 15.8%, reflecting disciplined pricing and cost management.
-
Reaffirmed Full-Year Guidance
Oscar Health reaffirmed its full-year 2026 outlook across all metrics, signaling management's confidence in achieving meaningful profitability for the year, despite the Q1 revenue miss.
-
Strong Revenue Growth and Membership Increase
Total revenue grew to $4.65 billion in Q1 2026 from $3.05 billion in Q1 2025, driven by a significant increase in total members to 3.17 million from 2.04 million year-over-year.
Analysis · OSCR · Finance
Oscar Health announced a substantial improvement in its financial performance for the first quarter of 2026, reporting a net income of $679.0 million, a significant reversal from the prior year's net loss. This strong profitability, coupled with an improved Medical Loss Ratio (MLR) and SG&A expense ratio, indicates enhanced operational efficiency. Despite Q1 revenue falling short of analyst estimates, the company's decision to reaffirm its full-year 2026 guidance suggests confidence in its ongoing strategy and future performance. This turnaround is a critical development for investors, especially following the substantial net loss reported in the fiscal year 2025.
How filings like this one have moved
In the 30 days to Oct 16, 2026, 36.8% of the 988 measured filings Wiseek scored 8 moved their stock by 5% or more by the next session's close. The median move was -0.55%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, OSCR was trading at $19.86 on NYSE in the Finance sector, with a market capitalization of approximately $4.8B. The 52-week trading range was $10.69 to $23.80. This filing was assessed with positive market sentiment and an importance score of 8 out of 10.